Skip to main content
. 2021 Mar 24;12:639095. doi: 10.3389/fphar.2021.639095

FIGURE 1.

FIGURE 1

Gefitinib inhibits proliferation of human NSCLC A549 cells. (A) A549, (B) CPAE and (C) IMR90 cells were treated with gefitinib for 24–72 h. After incubation, cell viability was measured by the CCK-8 assay. (D) A549 cells were incubated with gefitinib for 72 h, and then the populations of apoptotic and dead cells were analyzed using the MUSE Cell Analyzer. Experiments were performed in triplicate. Data represent mean ± SD. *p < 0.05, **p < 0.01 versus untreated control.